Global Human Genetically Engineered Vaccine Market Growth 2023-2029

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Years Considered
• 1.3 Research Objectives
• 1.4 Market Research Methodology
• 1.5 Research Process and Data Source
• 1.6 Economic Indicators
• 1.7 Currency Considered
• 1.8 Market Estimation Caveats

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Human Genetically Engineered Vaccine Annual Sales 2018-2029
  • 2.1.2 World Current & Future Analysis for Human Genetically Engineered Vaccine by Geographic Region, 2018, 2022 & 2029
  • 2.1.3 World Current & Future Analysis for Human Genetically Engineered Vaccine by Country/Region, 2018, 2022 & 2029
• 2.2 Human Genetically Engineered Vaccine Segment by Type
  • 2.2.1 Genetic Recombinant Vaccine
  • 2.2.2 Recombinant Subunit Vaccines
  • 2.2.3 Genetic Vaccine
• 2.3 Human Genetically Engineered Vaccine Sales by Type
  • 2.3.1 Global Human Genetically Engineered Vaccine Sales Market Share by Type (2018-2023)
  • 2.3.2 Global Human Genetically Engineered Vaccine Revenue and Market Share by Type (2018-2023)
  • 2.3.3 Global Human Genetically Engineered Vaccine Sale Price by Type (2018-2023)
• 2.4 Human Genetically Engineered Vaccine Segment by Application
  • 2.4.1 Hepatitis E
  • 2.4.2 Human Papillomavirus (HPV)
  • 2.4.3 Rotavirus
  • 2.4.4 Others
• 2.5 Human Genetically Engineered Vaccine Sales by Application
  • 2.5.1 Global Human Genetically Engineered Vaccine Sale Market Share by Application (2018-2023)
  • 2.5.2 Global Human Genetically Engineered Vaccine Revenue and Market Share by Application (2018-2023)
  • 2.5.3 Global Human Genetically Engineered Vaccine Sale Price by Application (2018-2023)

3 Global Human Genetically Engineered Vaccine by Company

• 3.1 Global Human Genetically Engineered Vaccine Breakdown Data by Company
  • 3.1.1 Global Human Genetically Engineered Vaccine Annual Sales by Company (2018-2023)
  • 3.1.2 Global Human Genetically Engineered Vaccine Sales Market Share by Company (2018-2023)
• 3.2 Global Human Genetically Engineered Vaccine Annual Revenue by Company (2018-2023)
  • 3.2.1 Global Human Genetically Engineered Vaccine Revenue by Company (2018-2023)
  • 3.2.2 Global Human Genetically Engineered Vaccine Revenue Market Share by Company (2018-2023)
• 3.3 Global Human Genetically Engineered Vaccine Sale Price by Company
• 3.4 Key Manufacturers Human Genetically Engineered Vaccine Producing Area Distribution, Sales Area, Product Type
  • 3.4.1 Key Manufacturers Human Genetically Engineered Vaccine Product Location Distribution
  • 3.4.2 Players Human Genetically Engineered Vaccine Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Human Genetically Engineered Vaccine by Geographic Region

• 4.1 World Historic Human Genetically Engineered Vaccine Market Size by Geographic Region (2018-2023)
  • 4.1.1 Global Human Genetically Engineered Vaccine Annual Sales by Geographic Region (2018-2023)
  • 4.1.2 Global Human Genetically Engineered Vaccine Annual Revenue by Geographic Region (2018-2023)
• 4.2 World Historic Human Genetically Engineered Vaccine Market Size by Country/Region (2018-2023)
  • 4.2.1 Global Human Genetically Engineered Vaccine Annual Sales by Country/Region (2018-2023)
  • 4.2.2 Global Human Genetically Engineered Vaccine Annual Revenue by Country/Region (2018-2023)
• 4.3 Americas Human Genetically Engineered Vaccine Sales Growth
• 4.4 APAC Human Genetically Engineered Vaccine Sales Growth
• 4.5 Europe Human Genetically Engineered Vaccine Sales Growth
• 4.6 Middle East & Africa Human Genetically Engineered Vaccine Sales Growth

5 Americas

• 5.1 Americas Human Genetically Engineered Vaccine Sales by Country
  • 5.1.1 Americas Human Genetically Engineered Vaccine Sales by Country (2018-2023)
  • 5.1.2 Americas Human Genetically Engineered Vaccine Revenue by Country (2018-2023)
• 5.2 Americas Human Genetically Engineered Vaccine Sales by Type
• 5.3 Americas Human Genetically Engineered Vaccine Sales by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Brazil

6 APAC

• 6.1 APAC Human Genetically Engineered Vaccine Sales by Region
  • 6.1.1 APAC Human Genetically Engineered Vaccine Sales by Region (2018-2023)
  • 6.1.2 APAC Human Genetically Engineered Vaccine Revenue by Region (2018-2023)
• 6.2 APAC Human Genetically Engineered Vaccine Sales by Type
• 6.3 APAC Human Genetically Engineered Vaccine Sales by Application
• 6.4 China
• 6.5 Japan
• 6.6 South Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 China Taiwan

7 Europe

• 7.1 Europe Human Genetically Engineered Vaccine by Country
  • 7.1.1 Europe Human Genetically Engineered Vaccine Sales by Country (2018-2023)
  • 7.1.2 Europe Human Genetically Engineered Vaccine Revenue by Country (2018-2023)
• 7.2 Europe Human Genetically Engineered Vaccine Sales by Type
• 7.3 Europe Human Genetically Engineered Vaccine Sales by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia

8 Middle East & Africa

• 8.1 Middle East & Africa Human Genetically Engineered Vaccine by Country
  • 8.1.1 Middle East & Africa Human Genetically Engineered Vaccine Sales by Country (2018-2023)
  • 8.1.2 Middle East & Africa Human Genetically Engineered Vaccine Revenue by Country (2018-2023)
• 8.2 Middle East & Africa Human Genetically Engineered Vaccine Sales by Type
• 8.3 Middle East & Africa Human Genetically Engineered Vaccine Sales by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers & Growth Opportunities
• 9.2 Market Challenges & Risks
• 9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

• 10.1 Raw Material and Suppliers
• 10.2 Manufacturing Cost Structure Analysis of Human Genetically Engineered Vaccine
• 10.3 Manufacturing Process Analysis of Human Genetically Engineered Vaccine
• 10.4 Industry Chain Structure of Human Genetically Engineered Vaccine

11 Marketing, Distributors and Customer

• 11.1 Sales Channel
  • 11.1.1 Direct Channels
  • 11.1.2 Indirect Channels
• 11.2 Human Genetically Engineered Vaccine Distributors
• 11.3 Human Genetically Engineered Vaccine Customer

12 World Forecast Review for Human Genetically Engineered Vaccine by Geographic Region

• 12.1 Global Human Genetically Engineered Vaccine Market Size Forecast by Region
  • 12.1.1 Global Human Genetically Engineered Vaccine Forecast by Region (2024-2029)
  • 12.1.2 Global Human Genetically Engineered Vaccine Annual Revenue Forecast by Region (2024-2029)
• 12.2 Americas Forecast by Country
• 12.3 APAC Forecast by Region
• 12.4 Europe Forecast by Country
• 12.5 Middle East & Africa Forecast by Country
• 12.6 Global Human Genetically Engineered Vaccine Forecast by Type
• 12.7 Global Human Genetically Engineered Vaccine Forecast by Application

13 Key Players Analysis

• 13.1 Pfizer
  • 13.1.1 Pfizer Company Information
  • 13.1.2 Pfizer Human Genetically Engineered Vaccine Product Portfolios and Specifications
  • 13.1.3 Pfizer Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
  • 13.1.4 Pfizer Main Business Overview
  • 13.1.5 Pfizer Latest Developments
• 13.2 Merck
  • 13.2.1 Merck Company Information
  • 13.2.2 Merck Human Genetically Engineered Vaccine Product Portfolios and Specifications
  • 13.2.3 Merck Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
  • 13.2.4 Merck Main Business Overview
  • 13.2.5 Merck Latest Developments
• 13.3 GSK
  • 13.3.1 GSK Company Information
  • 13.3.2 GSK Human Genetically Engineered Vaccine Product Portfolios and Specifications
  • 13.3.3 GSK Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
  • 13.3.4 GSK Main Business Overview
  • 13.3.5 GSK Latest Developments
• 13.4 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD.
  • 13.4.1 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Company Information
  • 13.4.2 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Product Portfolios and Specifications
  • 13.4.3 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
  • 13.4.4 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Main Business Overview
  • 13.4.5 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Latest Developments
• 13.5 Walvax Biotechnology Co., Ltd.
  • 13.5.1 Walvax Biotechnology Co., Ltd. Company Information
  • 13.5.2 Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
  • 13.5.3 Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
  • 13.5.4 Walvax Biotechnology Co., Ltd. Main Business Overview
  • 13.5.5 Walvax Biotechnology Co., Ltd. Latest Developments
• 13.6 Bharat Biotech
  • 13.6.1 Bharat Biotech Company Information
  • 13.6.2 Bharat Biotech Human Genetically Engineered Vaccine Product Portfolios and Specifications
  • 13.6.3 Bharat Biotech Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
  • 13.6.4 Bharat Biotech Main Business Overview
  • 13.6.5 Bharat Biotech Latest Developments
• 13.7 Chengdu Kanghua Biological Products Co., Ltd.
  • 13.7.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
  • 13.7.2 Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
  • 13.7.3 Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
  • 13.7.4 Chengdu Kanghua Biological Products Co., Ltd. Main Business Overview
  • 13.7.5 Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
• 13.8 South China Vaccine Corporation Limited
  • 13.8.1 South China Vaccine Corporation Limited Company Information
  • 13.8.2 South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
  • 13.8.3 South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
  • 13.8.4 South China Vaccine Corporation Limited Main Business Overview
  • 13.8.5 South China Vaccine Corporation Limited Latest Developments
• 13.9 Beijing Health Guard Biotechnology Inc.
  • 13.9.1 Beijing Health Guard Biotechnology Inc. Company Information
  • 13.9.2 Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Product Portfolios and Specifications
  • 13.9.3 Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
  • 13.9.4 Beijing Health Guard Biotechnology Inc. Main Business Overview
  • 13.9.5 Beijing Health Guard Biotechnology Inc. Latest Developments
• 13.10 CSL Limited
  • 13.10.1 CSL Limited Company Information
  • 13.10.2 CSL Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
  • 13.10.3 CSL Limited Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
  • 13.10.4 CSL Limited Main Business Overview
  • 13.10.5 CSL Limited Latest Developments
• 13.11 Emergent BioSolutions
  • 13.11.1 Emergent BioSolutions Company Information
  • 13.11.2 Emergent BioSolutions Human Genetically Engineered Vaccine Product Portfolios and Specifications
  • 13.11.3 Emergent BioSolutions Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
  • 13.11.4 Emergent BioSolutions Main Business Overview
  • 13.11.5 Emergent BioSolutions Latest Developments
• 13.12 Sanofi Pasteur
  • 13.12.1 Sanofi Pasteur Company Information
  • 13.12.2 Sanofi Pasteur Human Genetically Engineered Vaccine Product Portfolios and Specifications
  • 13.12.3 Sanofi Pasteur Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
  • 13.12.4 Sanofi Pasteur Main Business Overview
  • 13.12.5 Sanofi Pasteur Latest Developments
• 13.13 Serum Institute
  • 13.13.1 Serum Institute Company Information
  • 13.13.2 Serum Institute Human Genetically Engineered Vaccine Product Portfolios and Specifications
  • 13.13.3 Serum Institute Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
  • 13.13.4 Serum Institute Main Business Overview
  • 13.13.5 Serum Institute Latest Developments

14 Research Findings and Conclusion